Boston Therapeutics, Inc. Announces New Dosing Regimen for BTI320

LAWRENCE, Mass., Dec. 06, 2017 -- Boston Therapeutics, Inc is pleased to announce that effective sugar reduction with the investigative BTI320 formulation requires only one tablet. Findings were confirmed by the most recent proof-of-concept study conducted in high-risk Chinese subjects with pre-diabetes. A formulation, in the form of a dietary supplement, is currently available as SUGARDOWN^®, SUGARBLOCK and SUGARBALANCE in USA and Asia. Results of this study (Clinicaltrials.gov) were presented at the 77th American Diabetes Association (ADA) conference in June 2017 and exhibited that one tablet was effective in lowering the one and two-hour postprandial glucose levels in pre-diabetic subjects.

CEO, Carl W Rausch describes the significance of this change, “Moving from the two-tablet initial consumption to the single tablet has a two-fold benefit.  It will improve compliance and broaden a positive outcome experience. It will also enhance convenience and lower costs to individuals, immediately impacting the health economic trajectory of food related causes of metabolic diseases including diabetes, cardiovascular disease, neuropathies and retinopathies.”

The investigative BTI320 formulation has been shown to lower postprandial glucose excursions and significantly reduce glycemic variability in high-risk individuals with pre-diabetes.  In China alone, 110 million people were suffering from type 2 diabetes in 2015. This number is expected to grow to 151 million by 2040 (http://www.wpro.who.int/china/mediacentre/releases/2016/20160406/en/). The impact of treating people sooner than later cannot be understated and non-systemic option like BTI320 may have an important impact on the progression of disease.

About Boston Therapeutics, Inc.  www.bostonti.com 
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) is an innovator in design, development and commercialization of compounds, such as BTI-320, to treat diabetes and diabetes related complications. SUGARDOWN is a registered trademarks of Boston Therapeutics, Inc.

Forward Looking Statement
This press release includes forward-looking statements. These statements may be identified by words such as "feel," "believes," "expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future; risks associated with obtaining regulatory approval of our products; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC. Boston Therapeutics expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

Contact: Boston Therapeutics, Inc.
Carl Rausch, CEO 
Phone: 603-935-9799
Email: [email protected] 
www.bostonti.com